Drug Trial Radar · NCT04239625
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 20, 2019
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD
Conditions
- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy
- Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
ALK-001Drug
Oral administration of a pill for up to 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of ALK-001 assessed by incidence and/or clinically-significant changes of a combination of ocular and non-ocular adverse eventsTime frame: From baseline to 24 months
- Pharmacokinetic profile of ALK-001 derived from the concentrations of ALK-001 and metabolites in plasmaTime frame: Up to 24 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Alkeus Site
Phoenix, Arizona
Alkeus Site
Los Angeles, California
Alkeus Site
Aurora, Colorado
Alkeus Site
Gainesville, Florida
Alkeus Site
Indianapolis, Indiana
Alkeus Site
Grand Rapids, Michigan
Alkeus Site
Westbury, New York
Alkeus Site
Silverdale, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.